How to Build Your Biotech Company in 2024 (According to Founders)

11 October 2024

Angiex Featured in Labiotech’s Guide to Building a Biotech Company

Angiex was highlighted as one of only a handful of companies in Labiotech’s expert feature on building a successful biotech startup. In the article, Angiex’s CEO, Paul Jaminet, shared insights on how the supportive ecosystem in Cambridge has been essential to Angiex’s growth.

“For entrepreneurs, the advantage of having ready access to expertise, capital, and a company incubation ecosystem is hard to overstate,” Jaminet noted. He emphasized that the resources and community in Cambridge made it “immensely helpful” for Angiex to operate efficiently and advance its pioneering TM4SF1-directed therapies.

Labiotech’s recognition of Angiex highlights the company’s innovation in the biotech space and the importance of its location in fueling its progress toward next-generation cancer treatments. To see the entire story, read on.


About Angiex

Angiex Inc. is a privately held biopharmaceutical drug developer whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This delivery pathway may enable enhanced efficacy and therapeutic margin compared to conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class TM4SF1-directed ADC with potential to address high unmet medical needs.